The Trump administration announced it is extending its most-favored-nation drug pricing model to state Medicaid programs across all 50 states, a significant expansion of a policy that ties government drug payments to the lowest prices available in comparable wealthy nations.

The most-favored-nation approach requires that the government pay no more for prescription drugs than the lowest price paid by other developed countries for the same medications. The administration has framed the policy as a way to address longstanding disparities between what Americans pay for drugs and what citizens of other nations pay for the same treatments.

The expansion to state Medicaid programs broadens the reach of the policy beyond its prior scope, affecting the insurance program that covers tens of millions of low-income Americans. Medicaid is jointly funded by the federal government and individual states, making the pricing policy's extension to all 50 state programs a substantial shift in how the program negotiates pharmaceutical costs.

The pharmaceutical industry has historically opposed most-favored-nation pricing models, arguing they could reduce incentives for drug development and innovation. Supporters of the policy contend that drug manufacturers already sell medications profitably at lower prices in other countries, undermining that argument.

The announcement comes as drug pricing remains a top domestic policy issue, with bipartisan public support for lowering prescription costs. The administration's move applies the pricing framework at the state level through Medicaid, one of the largest single purchasers of prescription drugs in the United States.